Breaking News
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
July 20, 2018 - Exergaming can improve health in overweight and obese children, study shows
July 20, 2018 - Postmenopausal factors may impact heart-protective qualities of ‘good cholesterol’
July 20, 2018 - MRI and blood test combination results in improved prostate cancer diagnosis
July 20, 2018 - Update Health Professional and Consumer on Recent Recalled Products
July 20, 2018 - Researchers trace Parkinson’s damage in the heart
July 20, 2018 - Wearable device designed to measure cortisol in sweat
July 20, 2018 - Scientists demonstrate a new regulation mechanism for skeletal muscles
July 20, 2018 - Exposure to mobile phone radiation may negatively impact memory performance in adolescents
July 20, 2018 - SUSU scientists find alternative method to treat post-traumatic stress disorder syndrome
July 20, 2018 - Gestational diabetes may increase offspring’s heart disease risk
July 20, 2018 - New vaccine could protect unborn babies from Zika virus
July 20, 2018 - Researchers find high mercury and methylmercury concentrations in traditional Tibetan medicine
July 20, 2018 - Brief Safety Plan Intervention in ER Can Cut Suicidal Behavior
July 20, 2018 - The Mount Sinai Hospital receives accreditation as geriatric emergency department
July 20, 2018 - Toward a better understanding of Parkinson’s disease
July 20, 2018 - Med school communications office wins four national awards | News Center
July 20, 2018 - Professional baseball players with faster hand-eye coordination may have better batting performance
July 20, 2018 - Study looks into mechanisms that control sleep and wakefulness
July 20, 2018 - Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments
July 20, 2018 - Research reveals long-term efficacy of drug used to treat common cause of kidney failure
July 20, 2018 - Timing of dinner associated with breast and prostate cancer risks
July 20, 2018 - Health Tip: Performing the Heimlich Maneuver
July 20, 2018 - Nearly all adolescents have eating, activity or weight-related issues
July 20, 2018 - Sage launches new web-based tool that helps explore curated genomic analyses of Alzheimer’s
July 20, 2018 - High-performance porous polymeric material for chromatography applications
July 20, 2018 - New molecule shows great promise for future treatment of many cancers
July 20, 2018 - New research project investigates alternative treatments for eye infections
July 20, 2018 - Immune T cells are built to react as fast as possible, shows study
July 20, 2018 - ZHX2 protein could offer a new treatment strategy for kidney cancer
July 20, 2018 - EKF’s Quo-Lab POC HbA1c analyzer meets international quality targets for diabetes testing
July 20, 2018 - Health burdens of very high risk drinking are potentially large, study reveals
July 20, 2018 - Using miniature drug-filled nanocarriers to target headaches and tumors
July 20, 2018 - Researchers uncover cause for progression of prostate cancer to incurable stage
July 20, 2018 - Studies highlight issues regarding black lung, opioid overdose, police violence and more
July 20, 2018 - AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia
July 20, 2018 - Researchers are one step closer to developing eye drops to treat age-related macular degeneration (AMD)
July 20, 2018 - Patients maintain muscle mass five years after surgically induced weight loss
July 20, 2018 - AMSBIO introduces new, powerful CRISPR/Cas9 gene editing kits
July 20, 2018 - PureTech Health collaborates with Roche to advance oral administration of antisense oligonucleotides
July 20, 2018 - Analysis reveals disparities in cancer death rates among minority groups
July 20, 2018 - Dr Maddy Parsons receives Royal Microscopical Society Life Science Medal
July 20, 2018 - Study finds link between DNA methylation and non-alcoholic fatty liver disease
July 20, 2018 - Military personnel with head trauma and football players with suspected CTE show similar brain changes
July 20, 2018 - Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
July 20, 2018 - KKR is buying Envision Healthcare in a nearly $10B deal
Gyn Cancer Research Gets Short Shrift in Funding

Gyn Cancer Research Gets Short Shrift in Funding

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

NEW ORLEANS — Federal funding for medical research severely short changes gynecologic oncology when cancer lethality is taken into account, according to data presented here.

Among 13 common cancers included in the analysis, gynecologic cancers ranked near the bottom in funding support, as determined by federal spending per years of life lost for each type of cancer. Three gynecologic cancers used for the analysis — ovarian, cervical, and uterine — landed near the bottom of the list individually and collectively.

A comparison of ovarian and prostate cancer, for example, showed a mean expenditure of $85,000 per years of life lost (YLL) per 100 new cases of ovarian cancer. The mean soared beyond $1 million for prostate cancer. Even greater disparities resulted from analyses involving cervical and uterine cancer, Ryan Spencer, MD, of the University of Wisconsin in Madison, reported at the Society of Gynecologic Oncology (SGO) meeting.

“We observed that gynecologic cancers are disproportionately underfunded compared to most other cancer sites when using the funding-to-lethality score to standardize the impact of mortality, incidence, and person years of life lost to cancer death across various cancer sites,” said Spencer. “These disparities are seen when the data are aggregated and when the data are re-analyzed by individual year and when year-over-year trends are explored.

“Given current funding projections and the decline in clinical trial availability, these trends are likely to continue to worsen, rather than improve.”

SGO invited discussant Paola Gehrig, MD, of the University of North Carolina at Chapel Hill, noted that federal funding for clinical trials in all types of cancer has declined substantially in recent years. For example, the NCI funded 27% of new research proposals in 2001, but that declined to 12% by 2015. From 2008 to 2017, the number of fully funded NIH studies presented at the American Society of Clinical Oncology meeting decreased by 75%.

However, outcomes in at least some gynecologic cancers have not improved to the same degree as some common cancers during the decline in federal funding. Using her specialty of uterine cancer as an example, Gehrig noted that disease-specific mortality for uterine cancer increased 2% annually from 2010 to 2014.

Borrowing a statement from Spencer’s presentation, Gehrig concluded, “Without a correction, gynecologic cancers will continue to be underfunded and risk lagging behind other cancer sites in critical discoveries for cure and life prolongation, in this important era of immunotherapy, molecular targeting, and personalized medicine.”

The study had its origin in what Spencer described as a crisis in enrollment in gynecologic cancer clinical trials. From 2011 to 2016, enrollment in gyn cancer trials decreased by 90%, and the number of available trials declined by 68%. The objective was to determine the equability of NCI funding distributions across different types of cancer.

Data for the analyses came from the NCI Surveillance, Epidemiology, and End Results registry program and the Cancer Trends Progress Report and funding statistics for the years 2007-2014.

Investigators calculated a “funding-to-lethality” score for uterine, ovarian, and cervical cancer, as well as for 10 other types of cancer. The comparators included a mix of common diseases (breast, lung, prostate, colon), cancers with incidences similar to the gyn cancers, and cancers that affect only men (prostate, testicular).

To achieve a balance among cancer incidence, mortality, and burden of YLL, investigators determined YLL for each of the 13 cancers included in the analysis and then used federal funding for each of the cancers to calculate funding-to-lethality values.

In the overall analysis, prostate and breast cancer came out far ahead of all the other types of cancer. From 2007-2014, prostate cancer had a funding-to-lethality score of 1.811, which translated into $1,811,000 per YLL per 100 new cases. Breast cancer followed close behind with a score of 1.803 and $1,803,000 per YLL per 100 cases. Ovarian cancer ranked 9th (0.97, $97,000), cervical cancer ranked 10th (0.87, $87,000), and uterine cancer ranked 12th (0.057, $57,000). Testicular cancer came in last (0.044, $44,000).

Using the data for 2014, Spencer’s group compared ovarian and prostate cancers. Ovarian cancer had a mortality of 7.0191 deaths/100,000, versus 19.1189/100,000 for prostate cancer, and an incidence of 11,3496/100,000 versus 99.6716/100,000. Dividing mortality by incidence resulted in 0.618 deaths per new cancer for ovarian cancer and 0.192 for prostate cancer.

Multiplying the deaths per new cancer by 17.5 years of life lost to death by ovarian cancer and 9.9 years of life lost with each prostate cancer death yielded 1,282 YLL per 100 new cases of ovarian cancer and 189.9 YLL/100 for prostate cancer.

Finally, investigators divided the $91.5 million in funding by the YLL to arrive at $85,000/YLL/100 new cases and a funding-to-lethality score of 0.085 for ovarian cancer. The same calculations with $217.8 million in funding for prostate cancer resulted in $1,147,000 per YLL/100 and a funding-to-lethality score of 1.15.

Across the entire study period, the funding-to-lethality scores and funding per YLL per 100 new cases for the other cancers were:

  • Melanoma: -0.519 and $519,000
  • Colorectal: -0.422 and $442,000
  • Lung: -0.3 and $363,000
  • Leukemia: -0.353 and $353,000
  • Non-Hodgkin’s lymphoma: -0.284 and $284,000
  • Kidney: -0.112 and $112,000
  • Pancreas: -0.074 and $74,000

Spencer acknowledged several limitations of the study. The analysis did not account for funding from sources other than NCI. Funding gaps are likely multifactorial. A “correct” or “appropriate” funding-to-lethality score has not been determined.

Spencer and colleagues disclosed no relevant relationships with industry.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles